FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017

SAN FRANCISCO, Sept. 05, 2017 -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF monoclonal antibody in late-stage development for the treatment of idiopathic pulmonary fibrosis (IPF), at the European Respiratory Society (ERS) International Congress 2017 in Milan, Italy, September 9-13, 2017.  The podium presentation will report efficacy and safety results from a Phase 2b placebo-controlled, double-blind clinical study and safety results from combination safety sub-studies of pamrevlumab in IPF, and the poster session will include results from a preclinical study in a lung fibrosis model, comparing the effects of pamrevlumab with approved monotherapies and with combination therapies.

Below are details for the FibroGen presentations:

Poster Presentation
Title:  Therapeutic pamrevlumab (FG-3019) is more effective than pirfenidone or nintedanib in a mouse radiation-induced lung fibrosis model
Date and Time:  Sunday, September 10, 2017, 12:50 p.m. CEST
Location:  TP-15 (Hall 4)
Session and Presenter:  116 – Poster Presentation #PA908 (Lipson, et al.)
       
Oral Presentation
Title:  PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
Date and Time:  Tuesday, September 12, 2017, 10:45 a.m. CEST
Location:  Red (North)
Session and Presenter:  416 – Oral Presentation #OA3400 (Richeldi, et al.)

About Pamrevlumab
Pamrevlumab is a proprietary therapeutic antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. FibroGen is currently conducting clinical studies of pamrevlumab in idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). In desmoplastic or fibrotic cancers, such as pancreatic cancer, CTGF promotes abnormal proliferation of stromal and tumor cells. For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov.

About FibroGen, Inc. 
FibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD) and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS). Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.

Forward-Looking Statements
This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the Company's product candidate pamrevlumab, the potential safety and efficacy profile of our product candidates, and our clinical plans. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various no programs, including the enrollment and results from ongoing and potential future clinical trials for pamrevlumab, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contact
FibroGen, Inc.
Karen L. Bergman
Vice President, Investor Relations and Corporate Communications
1 (415) 978-1433
[email protected]